The business manufactures and supplies high-performance containment and sterile transfer valves to the largest global pharmaceutical, bio-pharmaceutical and chemicals companies. Operating across Europe, Asia and North America, its patented technology is used in the development and manufacture of medicines and vaccines by the top 50 global pharmaceutical manufacturers, facilitating the safe transfer of highly-potent and sterile powders.
ChargePoint Technology is a market leading manufacturer and innovator of specialist high containment and sterile transfer valves.
In January 2016 ChargePoint Technology secured investment from LDC to drive further international expansion. The investment by LDC, supporting Managing Director Chris Eccles and Sales Director Tony O’Sullivan in the buyout, will see LDC become a minority shareholder.
Following LDC’s investment, the business plans to capitalise on the strong and increasing demand for its solutions internationally, in particular North America, whilst accelerating sales of its innovative AseptiSafe® Bio product and investing in the development of new products, particularly in the aftercare market.
The investment from LDC will also enable management to embark on a targeted acquisition strategy to help it expand into adjacent sectors requiring containment and sterile transfer solutions.
We have created a strong platform for future growth and bringing LDC on board as an investment partner is a clear statement of intent regarding our future ambitions. With the team's track record in the sector and its in-depth experience of delivering international growth, we're confident we have the right people in place to help us take our market-leading technology even further afield. Chris Eccles, Managing Director, ChargePoint